 |
CEimpact PodcastAuthor: CEimpact
The CEimpact Podcast features two shows - GameChangers and Precept2Practice!The GameChangers Clinical Conversations podcast, hosted by Josh Kinsey, features the latest game-changing pharmacotherapy advances impacting patient care. New episodes arrive every Monday. Pharmacist By Design subscribers can earn CE credit for each episode. The Precept2Practice podcast, hosted by Kathy Schott, features information and resources for preceptors of students and residents. New episodes arrive on the third Wednesday of every month. Preceptor By Design subscribers can earn CE credit for each episode.To support our shows, give us a follow and check back each week for our latest episodes. Language: en-us Genres: Courses, Education, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
New Prescription Option for Fibromyalgia Treatment
Monday, 15 December, 2025
Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTAmanda (Mandy) Mullins, PharmD, BCPSClinical Pharmacist PractitionerVeterans AffairsPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcastCPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-25-371-H01-PInitial release date: 12/15/2025Expiration date: 12/15/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
